ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis
USA - NASDAQ:ABEO - US00289Y2063 - Common Stock
5.28 USD
-0.26 (-4.69%)
5.28 USD
0 (0%)
Overall ABEO gets a fundamental rating of 3 out of 10. We evaluated ABEO against 534 industry peers in the Biotechnology industry. ABEO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ABEO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
ABEO had negative earnings in the past year.
In the past year ABEO has reported a negative cash flow from operations.
In the past 5 years ABEO always reported negative net income.
In the past 5 years ABEO always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ABEO (23.25%) is better than 97.19% of its industry peers.
ABEO's Return On Equity of 34.99% is amongst the best of the industry. ABEO outperforms 97.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.25% | ||
| ROE | 34.99% | ||
| ROIC | N/A |
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ABEO (14310.50%) is better than 99.81% of its industry peers.
ABEO does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 14310.5% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABEO has been increased compared to 1 year ago.
The number of shares outstanding for ABEO has been increased compared to 5 years ago.
ABEO has a worse debt/assets ratio than last year.
2.2 Solvency
ABEO has an Altman-Z score of -2.14. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
ABEO's Altman-Z score of -2.14 is in line compared to the rest of the industry. ABEO outperforms 49.06% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that ABEO is not too dependend on debt financing.
ABEO has a worse Debt to Equity ratio (0.09) than 62.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.14 |
ROIC/WACCN/A
WACC8.65%
2.3 Liquidity
ABEO has a Current Ratio of 6.73. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
ABEO has a better Current ratio (6.73) than 67.79% of its industry peers.
A Quick Ratio of 6.65 indicates that ABEO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.65, ABEO is in the better half of the industry, outperforming 67.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.73 | ||
| Quick Ratio | 6.65 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.63% over the past year.
Looking at the last year, ABEO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)30.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ABEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.58% yearly.
Based on estimates for the next years, ABEO will show a very strong growth in Revenue. The Revenue will grow by 420.09% on average per year.
EPS Next Y174.57%
EPS Next 2Y43.89%
EPS Next 3Y38.62%
EPS Next 5Y27.58%
Revenue Next Year27374.5%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 43.14, the valuation of ABEO can be described as expensive.
Based on the Price/Forward Earnings ratio, ABEO is valued cheaply inside the industry as 90.07% of the companies are valued more expensively.
ABEO is valuated expensively when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.14 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ABEO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ABEO's earnings are expected to grow with 38.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.89%
EPS Next 3Y38.62%
5. Dividend
5.1 Amount
No dividends for ABEO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.28
-0.26 (-4.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners73.63%
Inst Owner Change-0.25%
Ins Owners5.63%
Ins Owner Change-6.29%
Market Cap270.76M
Revenue(TTM)400.00K
Net Income(TTM)57.24M
Analysts86.67
Price Target20.91 (296.02%)
Short Float %20.12%
Short Ratio9.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.37%
Min EPS beat(2)-36.14%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)1.78%
Min EPS beat(4)-53.14%
Max EPS beat(4)60.97%
EPS beat(8)4
Avg EPS beat(8)-1.46%
EPS beat(12)7
Avg EPS beat(12)23.44%
EPS beat(16)9
Avg EPS beat(16)14.87%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-309.64%
EPS NY rev (1m)0%
EPS NY rev (3m)405.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 43.14 | ||
| P/S | 676.9 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.66 | ||
| P/tB | 1.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.54
EYN/A
EPS(NY)0.12
Fwd EY2.32%
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0.01
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.25% | ||
| ROE | 34.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 14310.5% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 172.41% | ||
| Cap/Sales | 1328% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.73 | ||
| Quick Ratio | 6.65 | ||
| Altman-Z | -2.14 |
F-Score5
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)32.9%
Cap/Depr(5y)51.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-378.95%
EPS Next Y174.57%
EPS Next 2Y43.89%
EPS Next 3Y38.62%
EPS Next 5Y27.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year27374.5%
Revenue Next 2Y3315.94%
Revenue Next 3Y1164.88%
Revenue Next 5Y420.09%
EBIT growth 1Y-31.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-65.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-54.12%
OCF growth 3YN/A
OCF growth 5YN/A
ABEONA THERAPEUTICS INC / ABEO FAQ
Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to ABEO.
What is the valuation status for ABEO stock?
ChartMill assigns a valuation rating of 3 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.
Can you provide the profitability details for ABEONA THERAPEUTICS INC?
ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.